SCM
Superstring Capital Management Portfolio holdings
AUM
$187M
1-Year Est. Return
270.89%
This Fund
S&P 500
1 Year Est. Return
+270.89%
AUM
$187M
AUM Growth
+$85.3M
(+84%)
Holding
64
Top Buys
| 1 | +$13.7M | |
| 2 | +$6.85M | |
| 3 | +$5.79M | |
| 4 |
DFTX
Definium Therapeutics
DFTX
|
+$5.26M |
| 5 |
Axsome Therapeutics
AXSM
|
+$5.23M |
Top Sells
| 1 | +$7.99M | |
| 2 | +$5.65M | |
| 3 | +$5.39M | |
| 4 |
BridgeBio Pharma
BBIO
|
+$4.6M |
| 5 |
Summit Therapeutics
SMMT
|
+$4.08M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
IQVIA
IQV
$29.6B
| – | – |
-19,114
|
|
||
52
Jazz Pharmaceuticals
JAZZ
$11.7B
| – | – |
-40,893
|
|
||
53
Keros Therapeutics
KROS
$424M
| – | – |
-95,083
|
|
||
54
Nektar Therapeutics
NKTR
$1.91B
| – | – |
-51,270
|
|
||
55
Protagonist Therapeutics
PTGX
$5.89B
| – | – |
-20,358
|
|
||
56
uniQure
QURE
$654M
| – | – |
-33,175
|
|
||
57
RAPT Therapeutics
RAPT
$1.68B
| – | – |
-34,449
|
|
||
58
Regeneron Pharmaceuticals
REGN
$83.6B
| – | – |
-6,401
|
|
||
|
59
Summit Therapeutics
SMMT
$12.1B
| – | – |
-197,253
|
|
||
60
Sanofi
SNY
$115B
| – | – |
-50,407
|
|
||
61
Scholar Rock
SRRK
$4.44B
| – | – |
-39,521
|
|
||
62
Vir Biotechnology
VIR
$1.3B
| – | – |
-150,312
|
|
||
|
TECX
63
Tectonic Therapeutic
TECX
$430M
| – | – |
-119,286
|
|
||
|
BCAX
64
Bicara Therapeutics
BCAX
$964M
| – | – |
-175,902
|
|